Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	27.44B
Revenue (ttm)	11.86B
Net Income (ttm)	2.02B
Shares Out	894.67M
EPS (ttm)	2.19
PE Ratio	15.62
Forward PE	14.25
Dividend	1.35 (3.90%)
Ex-Dividend Date	Jul 8, 2024

Volume	5,210,470
Average Volume	5,214,636
Open	35.60
Previous Close	34.60
Day's Range	34.13 - 35.60
52-Week Range	34.07 - 44.72
Beta	0.28
RSI	33.33
Earnings Date	Mar 27, 2025

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,933
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2023, SHE:000513's revenue was 12.43 billion, a decrease of -1.58% compared to the previous year's 12.63 billion. Earnings were 1.95 billion, an increase of 2.32%.